̽»¨ºÏ¼¯

As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.

̽»¨ºÏ¼¯ today announced that two of its clinical supply experts will be participating in upcoming digital events, Clinical Trial Supply Europe and Clinical Trial Supply Roundtable Forum 2021.

EuropaBio today announced that ̽»¨ºÏ¼¯ has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.

Together, the addition of pDNA technology and production capabilities marks a significant milestone for ̽»¨ºÏ¼¯ Cell & Gene Therapy.

̽»¨ºÏ¼¯ today announced that it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals, for LUPKYNISâ„¢ (voclosporin), a drug to treat adult patients with lupus nephritis (LN).

̽»¨ºÏ¼¯ has completed the acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc., a developer of therapies to restore function and improve the lives of people with neurological disorders.

̽»¨ºÏ¼¯ today announced the launch of its CosmoPod® Duo softgel capsule technology for the delivery of topical skin treatments.

̽»¨ºÏ¼¯ today announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.

̽»¨ºÏ¼¯ and Decibel Therapeutics today announced they have signed an agreement for ̽»¨ºÏ¼¯ to provide Decibel with process and analytical development, and CGMP clinical manufacturing services, for Decibel’s lead investigational gene therapy product candidate, DB-OTO.